Mirati Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Mirati Therapeutics kazanç ve gelirin sırasıyla yıllık 29.9% ve 42.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 33% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -155.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

29.9%

Kazanç büyüme oranı

33.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	32.0%
Gelir büyüme oranı	42.2%
Gelecekteki özkaynak getirisi	-155.2%
Analist kapsamı	Good
Son güncelleme	20 Dec 2023

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BOVESPA:M2RT34 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	495	-408	33	-94	8
12/31/2025	312	-556	-271	-261	13
12/31/2024	173	-670	-448	-447	17
12/31/2023	62	-694	-553	-551	17
9/30/2023	38	-726	-596	-594	N/A
6/30/2023	27	-738	-591	-588	N/A
3/31/2023	19	-737	-604	-600	N/A
12/31/2022	12	-741	-575	-571	N/A
9/30/2022	12	-738	-586	-580	N/A
6/30/2022	78	-645	-496	-489	N/A
3/31/2022	73	-634	-449	-439	N/A
12/31/2021	72	-582	-399	-389	N/A
9/30/2021	74	-483	-336	-327	N/A
6/30/2021	13	-491	-365	-357	N/A
3/31/2021	13	-407	-328	-323	N/A
12/31/2020	13	-358	-276	-272	N/A
9/30/2020	12	-329	-241	-237	N/A
6/30/2020	2	-296	-196	-193	N/A
3/31/2020	2	-259	-174	-172	N/A
12/31/2019	3	-213	-149	-148	N/A
9/30/2019	6	-169	-127	-127	N/A
6/30/2019	5	-142	-114	-114	N/A
3/31/2019	5	-125	-97	-97	N/A
12/31/2018	13	-98	-70	-70	N/A
9/30/2018	9	-88	-63	-63	N/A
6/30/2018	9	-77	-58	-58	N/A
3/31/2018	9	-67	-55	-54	N/A
12/31/2017	N/A	-70	-65	-65	N/A
9/30/2017	N/A	-72	-67	-67	N/A
6/30/2017	N/A	-75	N/A	-70	N/A
3/31/2017	N/A	-79	N/A	-69	N/A
12/31/2016	N/A	-83	N/A	-68	N/A
9/30/2016	N/A	-82	N/A	-68	N/A
6/30/2016	N/A	-81	N/A	-65	N/A
3/31/2016	N/A	-75	N/A	-58	N/A
12/31/2015	N/A	-65	N/A	-51	N/A
9/30/2015	N/A	-57	N/A	-43	N/A
6/30/2015	N/A	-46	N/A	-37	N/A
3/31/2015	N/A	-42	N/A	-34	N/A
12/31/2014	N/A	-44	N/A	-33	N/A
9/30/2014	N/A	-45	N/A	-32	N/A
6/30/2014	N/A	-65	N/A	-27	N/A
3/31/2014	N/A	-62	N/A	-31	N/A
12/31/2013	N/A	-53	N/A	-29	N/A
9/30/2013	N/A	-48	N/A	-27	N/A
6/30/2013	N/A	-24	N/A	-26	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: M2RT34 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: M2RT34 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: M2RT34 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: M2RT34 şirketinin gelirinin (yıllık 42.2% ) BR pazarından (yıllık 7.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: M2RT34 şirketinin gelirinin (yıllık 42.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: M2RT34 3 yıl içinde kârsız olması bekleniyor.

Mirati Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin